This site is intended for healthcare professionals

Merck KGaA announces out-licensing agreement with TrialSpark/High Line Bio for sprifermin for osteoarthritis.

Read time: 1 mins
Published:27th Jan 2022
Merck KGaA, a leading science and technology company, has, through its subsidiary Ares Trading S.A., entered into an out-licensing agreement for sprifermin with TrialSpark/High Line Bio, New York, USA.

Sprifermin, a recombinant form of human fibroblast growth factor 18, is currently being investigated in patients with osteoarthritis (OA). As part of the agreement, Merck will receive an upfront payment as well as equity in TrialSpark/High Line Bio and is eligible for milestone payments related to delivering on certain development and commercial milestones, in addition to royalties on any future net sales.

TrialSpark/High Line Bio will assume full responsibility for the research, development and commercialization of sprifermin, which is in Phase II studies.

Condition: Pain:Osteoarthritis/ Knee
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.